Utilization of HPLC-Elisa to Assess Serum Levels of Thymosin α<sup>1</sup>Following Subcutaneous Administration to Human Subjects

Naylor, Paul; Naylor, Cartha W.; Sasaki, D.; Mutchníck, Milton G.

doi:10.1080/10826079408013530

Cited by 7 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RIA or HPLC-Elisa, respectively), were substantially similar albeit with some difference in the height of the peaks measured. The kinetic was described as similar to that reported for other proteins, such as interferon-alpha, where clearance is generally via filtration through the renal glomeruli followed by proximal tubular reabsorption with subsequent proteolytic degradation by lysosomal enzymes [74,77].…”

Section: Bioavailability and Pharmacokineticssupporting

confidence: 53%

“…In 1994, Naylor et al reported the development of an extraction-analysis procedure which combined high-performance liquid chromatography (HPLC) specificity with ELISA sensitivity to measure the levels of Ta1 following subcutaneous administration. The ELISA was required for detection since even following injection of 1.6 mg of Ta1, serum levels were not high enough to be measured with the UV detector of the HPLC unit [74].…”

Section: The Problem Of Quantificationmentioning

confidence: 99%

“…The first pharmacokinetic studies conducted in humans showed that the maximum achievable levels of Ta1 in serum or plasma is found between 2 and 6 h after subcutaneous injection of 1.6 mg Ta1 [74,76]. The results of those two studies, performed in different clinical situations and using different detection techniques (i.e.…”

Section: Bioavailability and Pharmacokineticsmentioning

confidence: 99%

See 2 more Smart Citations

Serum thymosin alpha 1 levels in normal and pathological conditions

Pica

Gaziano

Casalinuovo

et al. 2018

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

Thymosin alpha 1 (Ta1) is a natural occurring peptide hormone that is crucial for the maintenance of the organism homeostasis. It has been chemically synthesized and used in diseases where the immune system is hindered or malfunctioning. Areas covered: Many clinical trials investigate the Ta1 effects in patients with cancer, infectious diseases and as a vaccine enhancer. The number of diseases that could benefit from Ta1 treatment is increasing. To date, questions remain about the physiological basal levels of Ta1 and the most effective dose and schedule of treatment. Evidence is growing that diseases characterized by deregulation of immune and/or inflammatory responses are associated with serum levels of Ta1 significantly lower than those of healthy individuals: to date, B hepatitis, psoriatic arthritis, multiple sclerosis and sepsis. The sputum of cystic fibrosis patients contains lower levels of Ta1 than healthy controls. These data are consistent with the role of Ta1 as a regulator of immunity, tolerance and inflammation. Expert opinion: Low serum Ta1 levels are predictive and/or associated with different pathological conditions. In case of Ta1 treatment, it is crucial to know the patient's baseline serum Ta1 level to establish effective treatment protocols and monitor their effectiveness over time.

show abstract

Section: Bioavailability and Pharmacokineticssupporting

confidence: 53%

Section: The Problem Of Quantificationmentioning

confidence: 99%

Section: Bioavailability and Pharmacokineticsmentioning

confidence: 99%

See 1 more Smart Citation

Serum thymosin alpha 1 levels in normal and pathological conditions

Pica

Gaziano

Casalinuovo

et al. 2018

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

show abstract

“…Many companies, such as Sigma, Promega, and Perkin Elmer Life Science, have developed ELISA kits for peptides. Additionally, LC-ELISA was used for antigen screening by Naylor in 1994 [35]. However, no attempt has been made to combine LC-ELISA and LC-MS to identify epitopic peptides.…”

Section: Introductionmentioning

confidence: 99%

Epitopic Peptides Identified by LC–ELISA and LC–MS

Zhou

Wang

2011

Chromatographia

View full text Add to dashboard Cite

A new strategy of a liquid chromatography (LC)-enzyme linked immunosorbent assay (ELISA) combined with liquid chromatography-mass spectrometry (LC-MS) was developed to identify the epitopic peptides for the antigen in Streptococcus suis. Metallendopeptidase, a potential antigen for S. suis, was digested by trypsin. The tryptic solution was separated by LC under optimal condition and collected into tubes. After it was dried using a cooling vacuum, the immunogenecity of peptides in each tube was investigated by ELISA against its corresponding antibody. All peptides in each tube with positive signals based on ELISA results were identified by LC-MS. Accordingly, six putative peptides of metallendopeptidase were found and synthesized, all of which possessed high antigenicity recognized by the antibody.

show abstract